Johnson & Johnsons (NYSE: JNJ) Janssen's subsidiary announced that she wanted to extend the use of her nasal spray, Spravato, as a short-term treatment for use with traditional oral antidepressants.
Spravato, which was approved last month in Europe as a treatment for depression, focuses on patients with treatment resistance depression who have failed to improve their symptoms by other means. It can also deal with patients with severe depressive disorders suffering from suicidal intent with intent – the demographics sought in Europe.
Janssen's submission – Aspire I and Aspire II – is supported by two phase 3 clinical studies – both of which showed good results in reducing depression properties while stepping up placebo spraying. One test found that approximately 70% of patients responded well to Spravato, with a 50% reduction in the severity of symptoms. In addition to being a fast acting treatment, and increasing depression symptoms as quickly as four times after the first dose, Spravato patients are also well accepted. The most common side effects were dizziness, headache, and nausea.
More details about Spravato
Spravato – also known as esketamine – is a modified method of ketamine. Unlawfully used as hallucinogen, ketamine can be used to stimulate anesthesia in patients. Johnson & Johnson have high expectations for the nasal spray, which has a price price of $ 6,785 for the first month of the patient's dosing schedule.
The pharmaceutical drug was originally approved by the Student Food and Drug Administration in March 2019, and Janssen is now awaiting a response to a new supplementary Drug Application filed for Spravato in October.